Foundation Medicine Receives the US FDA’s Approval of FoundationOne CDx for Eli Lilly's Retevmo to Treat Solid Tumors
Shots:
- The US FDA has approved FoundationOne CDx as a companion diagnostic for Eli Lilly’s Retevmo (selpercatinib)
- Retevmo was approved by the US FDA in 2022 for the treatment of adult patients with LA or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options
- FoundationOne CDx, a tissue-based comprehensive genomic profiling test that analyzes 300+ cancer-related genes for genomic alterations in a patient’s tumor
Ref: Business Wire | Image: Foundation Medicine
Related News:- Eli Lilly Collaborated with Foundation Medicine to Develop FoundationOne CDx and FoundationOne Liquid CDx for Retevmo to Treat Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
